Zacks.com on MSN5d
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...
The Pharma Letter3d
Uvax Bio appoints Kevin O’Neill as interim chief executive
Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...
Pharmabiz5d
Merck receives positive EU CHMP opinion for Capvaxive for pneumococcal vaccination in adults
Merck, known as MSD outside of the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of ...
Daily3d
Centers for Disease Control and Prevention (CDC) Lowers Pneumococcal Vaccination Age to 50
Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...
Canada5d
NACI statement on public health recommendations on pneumococcal vaccines
NACI has also recommended 13-valent conjugate pneumococcal vaccine, PNEU-C-13, for adults; however, in publicly funded programs, this recommendation is limited to individuals with risk factors for IPD ...
pharmaphorum5d
Vaxcyte's pneumococcal vaccine win points to Prevnar battle
In June, MSD got FDA approval for a 21-valent vaccine ... It expects the pneumococcal vaccine market to reach a value of around $13 billion by 2027, driven primarily by growth in the adult ...
pharmaphorum5d
FDA says yes to MSD’s 21-valent adult pneumococcal jab
The approval is the strongest challenge yet to Pfizer’s pneumococcal vaccine franchise, led by its 20-valent Prevnar 20 ... as strongly as the newer conjugate vaccines. It brought in $412 ...